The UK and US have established a major commercial pact that will maintain no tariffs on UK pharmaceutical products entering the American market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has committed to boost expenditure on medicines through the NHS. This move ensures that tariffs on these crucial exports will remain at nothing for a period of the next three years.
This development follows previous threats to hike duties on patented drug imports, with figures discussed up to 100%.
"This arrangement with the Britain strengthens the worldwide climate for new treatments and brings much-needed balance to transatlantic medicine commerce," a statement noted.
Economic Significance
Medicines represent one of the the United Kingdom's largest exports to the United States, which is clearly the primary market for large UK drugmakers.
Export figures show that in the year prior to September, the UK sold medicines worth billions to the US. This figure made up a significant portion of all goods exports in that timeframe.
"This agreement protects jobs, increases funding and paves the way for the UK to emerge as a worldwide center for biotech and pharma," the Business and Trade Secretary remarked.
Specific UK Commitments
The deal includes several specific changes from the United Kingdom:
- Price Threshold Increase: The UK will increase the price threshold at which it considers new therapies to be prohibitively costly by 25%.
- Higher Drug Budget: There is a target to raise overall health service expenditure on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Payback Limit: The amount pharmaceutical firms must refund to the NHS to prevent overspending will be limited at fifteen percent. Previously, rebates topped 20%.
Industry Background
This agreement takes place against a ongoing tension between the drug companies and the British authorities over medicine costs and approval rates.
This friction were intensified by arguments that American customers were charged several times more for the equivalent treatments than patients in the UK and Europe.
In recent months, several major manufacturing plans in the UK have been halted or scrapped, while multi-billion-dollar investments have been directed toward American operations.
One official stated that the NHS needed to spend more on treatments, noting that its spending on drugs had shrunk as a proportion of its resources over the past decade.
